|1.||Senyah, Yaw: 1 article (05/2011)|
|2.||Stemmelin, Jeanne: 1 article (05/2011)|
|3.||Featherstone, Robert E: 1 article (05/2011)|
|4.||Giardino, Odessa: 1 article (05/2011)|
|5.||Borowsky, Beth: 1 article (05/2011)|
|6.||Griebel, Guy: 1 article (05/2011)|
|7.||Arad, Michal: 1 article (05/2011)|
|8.||De Levie, Amaya: 1 article (05/2011)|
|9.||Barak, Segev: 1 article (05/2011)|
|10.||Black, Mark D: 1 article (05/2011)|
|1.||Schizophrenia (Dementia Praecox)
05/01/2011 - "These studies investigated the effects of the CB1 receptor antagonist, AVE1625, in acute pharmacological and neurodevelopmental models of schizophrenia. "
05/01/2011 - "These preclinical data suggest that AVE1625 may be useful to treat the cognitive deficits in schizophrenia and as a co-treatment with currently available antipsychotics. "
05/01/2011 - "AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents."
|4.||Body Weight (Weight, Body)
10/01/2010 - "Combination of OLZ treatment with the CB1-antagonist AVE1625 attenuated body weight gain in rats."
10/01/2010 - "Coadministration of OLZ and AVE1625 (10 mg/kg orally once daily) attenuated body weight gain, diminishing the enhanced food intake while maintaining increased energy expenditure and decreased motility. "
10/01/2010 - "We further analyzed whether, and by which mechanism, the CB1-antagonist AVE1625 might attenuate OLZ-induced body weight gain. "
|1.||CB1 Cannabinoid Receptor (CB1 Receptor)
|2.||Antipsychotic Agents (Antipsychotics)